Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Masateru Kurumi is active.

Publication


Featured researches published by Masateru Kurumi.


International Archives of Allergy and Immunology | 2000

Involvement of Eosinophils in the Early-Phase Allergic Reaction in a Guinea Pig Rhinitis Model

Norio Imai; Atsushi Miyahara; Yuji Yamazaki; Reiko Homma; Yoshitaka Ino; Masateru Kurumi

Background: Eosinophils are found in the nasal lavage fluid (NLF) and nasal biopsies of patients with allergic rhinitis after a nasal antigen challenge, and associated not only with a late-phase allergic reaction (LPR) but also an early phase allergic reaction (EPR). Numerous studies have been carried out to clarify the participation of eosinophils in LPR or airway hyperresponsiveness. However, there has been no published report describing in detail the role of eosinophils during EPR. To better understand the involvement of eosinophils in EPR, we studied the effects of repeated antigen challenges on nasal airway responsiveness and eosinophilic inflammation in EPR using a guinea pig rhinitis model. Methods: Nasal airway responsiveness was measured as the nasal airway resistance (NAR) after nasal antigen provocation. Eosinophilic inflammation during EPR was assessed by nasal lavage and histopathological examination using two groups of animals: those in group 1 were subjected to a sensitization pretreatment only, and those in group 2 were subjected to a pretreatment of sensitization followed by repeated nasal challenges. Results: Repeated antigen challenges induced nasal hyperresponsiveness as indicated by a decrease in the antigen provocation dose and a significant increase in NAR. Furthermore, significant increases in eosinophil counts, eosinophil peroxidase (EPO) activity and protein content in NLF during EPR were observed following antigen provocation in group 2. There were significant correlations between the levels of these parameters, and albumin was the most prevalent of the proteins in NLF. Histopathological examination showed that the degree of eosinophil infiltration into the lamina propria of the nasal mucosa of the animals in group 2 was significantly and apparently higher than in group 1. Particularly, epithelial disruption and mucosal edema were significantly elevated after antigen provocation in group 2. Conclusions: These results suggest that chronic eosinophil accumulation is induced by repeated antigen challenges in the nasal tissue, and that once antigen provocation occurs, eosinophils in the tissue are activated and responsible for the amplification of EPR such as vascular permeability and mucosal edema.


Yakugaku Zasshi-journal of The Pharmaceutical Society of Japan | 1995

[Inhibitory effects of sepimostat mesilate (FUT-187) on the activities of trypsin-like serine proteases in vitro].

Kazunori Nakamura; Ayako Johmura; Minoru Oda; Yoshitaka Ino; Hiroyuki Uchiyama; Hisaya Ohtani; Hiroyuki Miyazaki; Masateru Kurumi; Yushiro Akizawa; Toshinori Oka

Inhibitory activities of FUT-187 on trypsin-like serine proteases were compared using camostat mesilate (camostat), and 4-(4-guanidino benzoyloxy)-phenyl acetic acid methanesulfonate (GBPA) known as an active metabolite of camostat in the blood. Ki values of FUT-187 on the competitive inhibition mechanism were 0.097 microM for trypsin, 0.029 microM for pancreatic kallikrein, 0.61 microM for plasma kallikrein, 0.57 microM for plasmin, 2.5 microM for thrombin, 20.4 microM for factor Xa and 6.4 microM for C1r. However, FUT-187 acted as a noncompetitive inhibitor for factor XIIa and an uncompetitive inhibitor for C1s, and Ki values for these proteases were 0.021 and 0.18 microM, respectively. Ki values of camostat for these proteases were in the range of 0.037 to 96.4 microM, and those of GBPA for the above proteases except trypsin and plasma kallikrein were higher than those of FUT-187. The inhibitory activity of FUT-187 on trypsin was not reduced by the addition of the serum at 10%, whereas, that of GBPA was reduced (4.3 fold) in terms of IC50 values. The concentration of FUT-187 required to double APTT (activated partial thromboplastin time) was 1.09 microM, while GBPA, by concentrations up to 1 mM failed to double APTT. The kinin formation by glandular kallikrein in the rat plasma was inhibited by FUT-187 with IC50 value of 0.024 microM, while camostat revealed no inhibition by concentrations up to 1 microM. The complement-mediated hemolyses in the classical and alternative pathways were also inhibited by FUT-187 with IC50 values of 0.17 and 3.5 microM, respectively, the corresponding values for camostat being 350 and 150 microM, respectively. It is concluded that FUT-187 is a potent and selective inhibitor of trypsin-like serine proteases, and its inhibitory activities are stronger than those of camostat on glandular kallikrein, factor XIIa and C1s in complement pathway.


Thrombosis Research | 2001

Effect of Sepimostat Mesilate on Experimental Venous Thrombosis in Rats

Akinori Tsuruda; Satoshi Kanno; Hisaya Ohtani; Rie Suzuki; Masaki Nishioka; Yoshiko Koshiyama; Masateru Kurumi

Sepimostat mesilate (FUT-187: 6-amidino-2-naphthyl 4-[(4,5-dihydro-1H-imidazol-2-yl) amino] benzoate dimethane sulfonate) is a newly synthesized serine protease inhibitor. In the present study, the oral administration of FUT-187 inhibited stasis-induced venous thrombosis in rats. We supposed that such effect of this compound was caused by its inhibitory effect on coagulation. However, the dose of FUT-187 that was effective at inhibiting thrombosis (10 and 30 mg/kg, po) had no effect on the plasma recalcification time (PRCT), activated partial thromboplastin time (APTT) and prothrombin time (PT) in rats. Therefore, we investigated the fibrinolytic activity of FUT-187 in rat plasma. The results revealed that rat plasma after FUT-187 administration exhibited increased amidolytic activity for a plasmin-, tissue-type plasminogen activator (t-PA)-, urokinase-type plasminogen activator (u-PA)-, factor Xa-, factor XIa- and factor XIIa-sensitive synthetic peptide substrate. On the other hand, the inhibitory effect of FUT-187 in the thrombosis model was not affected by additional treatment with epsilon-amino-n-caproic acid (EACA), a plasmin-mediated fibrinolysis inhibitor. These results suggest that even if FUT-187 enhanced fibrinolysis, it would be independent of a plasmin-mediated fibrinolytic pathway. To characterize the fibrinolytic activity, which might reduce the thrombus weight in the thrombosis model administered FUT-187, we carried out fibrinogen zymography, and clarified that FUT-187 enhanced the formation of a 20-kDa fibrinolytic fragment. Interestingly, this fragment was not affected by t-PA. Consequently, we consider that the inhibitory effect of FUT-187 on venous thrombosis model is caused by fibrinolysis, which is attributable to the 20-kDa fragment, rather than by inhibition of thrombus formation.


Advances in Experimental Medicine and Biology | 1986

New synthetic substrate for kallikrein and its application.

Setsuro Fujii; Yuji Hitomi; Kenjiro Kimura; Masao Ishii; Masateru Kurumi; Takuo Aoyama

We developed a new synthetic substrate, Pro-Phe-Arg-alpha-naphthyl ester, for kallikrein. We found that this substrate had higher specificity and sensitivity for kallikrein and was applied for the preparation of zymogram and for the histochemical demonstration. With Pro-Phe-Arg-alpha-NE as substrate, the minimum detectable concentration of human urinary kallikrein was about 0.001 KU and then kallikrein could be determined with 25 microliter of human urine. We also found the possibility that occurring of abnormalities during pregnancy were predicted by the determination of urinary kallikrein of pregnants. Zymograms were prepared for various kinds of kallikrein using this substrate. The localization of kallikrein-like enzyme in rat kidneys was defined by the application this substrate for histochemistry. Moreover, cytochemical demonstrations of leucocytes in human blood were done using Ts-Lys-alpha-NE and Ac-Tyr-alpha-NE.


Japanese Journal of Pharmacology | 1986

Pharmacological Studies of FUT-175, Nafamostat Mesilate V. Effects on the Pancreatic Enzymes and Experimental Acute Pancreatitis in Rats

Masahiro Iwaki; Yoshitaka Ino; Akemi Motoyoshi; Masayuki Ozeki; Takuo Sato; Masateru Kurumi; Takuo Aoyama


Archive | 1984

Novel amidine compound

Setsuro Fujii; Toyoo Nakayama; Shigeki Nunomura; Ryoji Matsui; Shinichi Watanabe; Kimio Sudo; Toshiyuki Okutome; Masateru Kurumi; Yojiro Sakurai; Takuo Aoyama


Chemical & Pharmaceutical Bulletin | 1985

Synthesis and structure ― activity study of protease inhibitors. IV: Amidinonaphthols and related acyl derivatives

Takuo Aoyama; Toshiyuki Okutome; Toyoo Nakayama; Takashi Yaegashi; Ryoji Matsui; Shigeki Nunomura; Masateru Kurumi; Yojiro Sakurai; Setsuro Fujii


Archive | 1984

Amidine compounds and anticomplement agent comprising same

Setsuro Fujii; Toshiyuki Okutome; Toyoo Nakayama; Takashi Yaegashi; Masateru Kurumi


Chemical & Pharmaceutical Bulletin | 1984

Synthesis and Structure-Activity Study of Protease Inhibitors. III. Amidinophenols and Their Benzoyl Esters

Takashi Yaegashi; Shigeki Nunomura; Toshiyuki Okutome; Toyoo Nakayama; Masateru Kurumi; Yojiro Sakurai; Takuo Aoyama; Setsuro Fujii


Archive | 1988

6-amino-2-naphthyl 4-gusnichinobenzoate derivatives and pharmaceutical composition containing them

Setsurou Fujii; Toshiyuki Okutome; Toyoo Nakayama; Shigeki Nunomura; Kimio Sudo; Shinichi Watanabe; Masateru Kurumi; Takuo Aoyama

Collaboration


Dive into the Masateru Kurumi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge